Compare Stocks → Could this Tiny Biotech End Disease Forever? (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ARYDNASDAQ:EIGRNASDAQ:GNFTNASDAQ:GRPH Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARYDARYA Sciences Acquisition Corp IV$11.37+0.2%$11.28$10.43▼$11.39$85.73M-0.0145,243 shs319 shsEIGREiger BioPharmaceuticals$1.73-9.2%$4.60$1.10▼$43.35$2.55M1.83103,866 shs137,800 shsGNFTGenfit$3.59+1.1%$3.55$2.89▼$4.75$178.89M1.0613,709 shs982 shsGRPHGraphite Bio$3.18-2.8%$13.89$2.01▼$4.26$185.20M0.2282,405 shs328,300 shs10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARYDARYA Sciences Acquisition Corp IV0.00%+0.18%+0.62%+2.16%+8.82%EIGREiger BioPharmaceuticals0.00%0.00%-25.00%-71.20%-94.72%GNFTGenfit-0.57%+0.29%-0.52%-1.40%-17.84%GRPHGraphite Bio0.00%0.00%0.00%-84.44%-85.89%Incredible Opportunity to Retire FAST! (Ad)A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guideMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARYDARYA Sciences Acquisition Corp IVN/AN/AN/AN/AN/AN/AN/AN/AEIGREiger BioPharmaceuticals4.2676 of 5 stars3.55.00.04.21.21.70.6GNFTGenfit0.5859 of 5 stars3.52.00.00.00.00.00.0GRPHGraphite BioN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARYDARYA Sciences Acquisition Corp IVN/AN/AN/AN/AEIGREiger BioPharmaceuticals3.00Buy$120.006,856.52% UpsideGNFTGenfit3.00Buy$11.00206.41% UpsideGRPHGraphite BioN/AN/AN/AN/ACurrent Analyst RatingsLatest EIGR, GRPH, ARYD, and GNFT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/5/2024GNFTGenfitHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00(Data available from 5/8/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARYDARYA Sciences Acquisition Corp IVN/AN/AN/AN/A($3.49) per shareN/AEIGREiger BioPharmaceuticals$15.77M0.16N/AN/A$37.68 per share0.05GNFTGenfit$41.31M4.33N/AN/A$1.48 per share2.43GRPHGraphite BioN/AN/AN/AN/A$3.15 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARYDARYA Sciences Acquisition Corp IV-$2.13MN/A0.00∞N/AN/A-9.83%-5.41%N/AEIGREiger BioPharmaceuticals-$96.78M-$59.16N/A∞N/A-590.80%-332.49%-99.77%5/9/2024 (Estimated)GNFTGenfit-$31.27MN/A0.00N/AN/AN/AN/AN/A7/4/2024 (Estimated)GRPHGraphite Bio-$124.65M-$2.23N/AN/AN/AN/A-33.12%-27.96%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARYDARYA Sciences Acquisition Corp IVN/AN/AN/AN/AN/AEIGREiger BioPharmaceuticalsN/AN/AN/AN/AN/AGNFTGenfitN/AN/AN/AN/AN/AGRPHGraphite BioN/AN/AN/AN/AN/ALatest EIGR, GRPH, ARYD, and GNFT DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date3/15/2024GRPHGraphite Bio$7.2128.93%3/15/20243/18/20243/21/2024(Data available from 1/1/2013 forward)DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARYDARYA Sciences Acquisition Corp IVN/A0.010.01EIGREiger BioPharmaceuticalsN/A3.313.24GNFTGenfit0.922.942.94GRPHGraphite BioN/A39.2039.20OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARYDARYA Sciences Acquisition Corp IV48.08%EIGREiger BioPharmaceuticals62.46%GNFTGenfit2.24%GRPHGraphite Bio54.32%Insider OwnershipCompanyInsider OwnershipARYDARYA Sciences Acquisition Corp IV53.45%EIGREiger BioPharmaceuticals4.22%GNFTGenfit4.20%GRPHGraphite Bio38.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableARYDARYA Sciences Acquisition Corp IV37.54 million3.51 millionNot OptionableEIGREiger BioPharmaceuticals561.48 million1.42 millionOptionableGNFTGenfit15949.83 million47.74 millionNot OptionableGRPHGraphite Bio658.24 million35.87 millionNot OptionableEIGR, GRPH, ARYD, and GNFT HeadlinesSourceHeadlineLENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progressfinance.yahoo.com - March 21 at 6:58 PMGRPH Mar 2024 5.000 putfinance.yahoo.com - March 15 at 7:56 PMVERI, STI and VERB among mid-day moversseekingalpha.com - March 15 at 2:53 PMGRPH Mar 2024 7.500 callfinance.yahoo.com - March 15 at 2:53 PMGraphite Bio, Inc. (GRPH)finance.yahoo.com - March 14 at 11:51 PMGraphite Bio to Pay Special Dividend Linked to Lenz Therapeutics Mergermarketwatch.com - March 10 at 2:35 AMGraphite Bio announces $1.03 per share special dividendau.investing.com - March 8 at 11:26 PMGraphite Bio declares special $1.03 dividendmsn.com - March 8 at 6:23 PMGraphite Bio Declares Special Dividend In Connection with Proposed Merger with Lenz Therapeuticsbusinesswire.com - March 8 at 5:00 PMSwitch Finishes - Matt Graphite Blackarchdaily.com - March 6 at 6:05 PMGRAPHITE BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Graphite Bio, Inc. - GRPHbusinesswire.com - February 27 at 3:31 PMSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Graphite Bio, Inc. (GRPH)markets.businessinsider.com - February 2 at 3:50 PMGraphite Bio: Reverse Merger Leading Into Big Special Dividend And Q2 Phase 3 Trialseekingalpha.com - December 25 at 7:34 AMGraphite Bio (GRPH) Price Target Increased by 40.00% to 7.14msn.com - November 27 at 8:19 AMGRAPHITE BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Graphite Bio, Inc. - GRPHbusinesswire.com - November 17 at 11:32 PMGRAPHITE BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Graphite Bio, Inc. - GRPHbusinesswire.com - November 17 at 8:02 PMShareholder Alert: Ademi LLP investigates whether Graphite Bio, Inc. has obtained a Fair Price in its transaction with LENZ Therapeuticsbenzinga.com - November 16 at 7:29 PMGraphite and LENZ merge to focus on presbyopia programsthepharmaletter.com - November 16 at 2:29 PMShattered dream of sickle cell disease cure to end in reverse merger for Peninsula biotechbizjournals.com - November 16 at 2:29 PMWhat Makes Graphite Bio, Inc. (GRPH) a New Buy Stockfinance.yahoo.com - November 16 at 2:29 PMGRPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Graphite Bio, Inc. Is Fair to Shareholdersbenzinga.com - November 15 at 4:06 PMGraphite Bio To Merge With LENZ Therapeutics; Stock Down In Pre-marketmarkets.businessinsider.com - November 15 at 8:53 AMLENZ Therapeutics and Graphite Bio Announce Merger Agreementfinance.yahoo.com - November 15 at 8:53 AMGraphite Bio Inc GRPHmorningstar.com - November 9 at 4:06 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsARYA Sciences Acquisition Corp IVNASDAQ:ARYDArya Sciences Acquisition Corp IV does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It focuses on acquiring North American or European companies in the life sciences and medical technology sectors. The company was incorporated in 2020 and is based in New York, New York.Eiger BioPharmaceuticalsNASDAQ:EIGREiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.GenfitNASDAQ:GNFTGenfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.Graphite BioNASDAQ:GRPHGraphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. The company offers GPH102 for the treatment of beta-thalassemia; and GPH201 for the treatment of XSCID, a life-threatening disease for multiple mutations in a single gene. It also offers GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is based in South San Francisco, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.